Deregulated transcription factors in cancer cell metabolisms and reprogramming. (November 2022)

• Record Type: Journal Article
• Authors: Kant, Rajni; Manne, Rajesh Kumar; Anas, Mohammad; Penugurti, Vasudevarao; Chen, Tingjin; Pan, Bo-Syong; Hsu, Che-Chia; Lin, Hui-Kuan
• Is Part Of: Seminars in cancer biology. Volume 86(2023)Part 3
• Page Start: 1158
• Page End: 1174
• Publication Date: 2022-11
• Subjects: ACC1 Acetyl-CoA carboxylase 1 -- ACOX1/2 acyl-CoA oxidase 1 and 2 -- ACYL ATP citrate lyase -- Akt protein kinase B -- AMPK AMP-activated protein kinase -- AR androgen receptor -- ASCT2/SLC1A5 alanine serine cysteine transporter 2/solutecarrier family 1 member 5 -- BCAAs branched-chain amino acids -- BCAT1 branched chain amino acid transaminase 1 -- BNIP3 BCL2/adenovirus E1B 19 kd-interacting protein 3 -- CAD carbamoyl-phosphate synthetase 2, aspartatetranscarbamylase, and dihydroorotase -- CBP CREB binding protein -- ChREBP carbohydrate-response element-binding protein -- COX cytochrome c oxidase -- CPT1A/CPT2 carnitine palmitoyltransferase IA/2 -- E2F E2 factor -- ELOVL6 ELOVL Fatty Acid Elongase 6 -- ENO1 enolase 1 -- ERs estrogen receptors -- FASN fatty acid synthase -- FOXO forkhead box protein O -- G6PD glucose-6-phosphate dehydrogenase -- GAMT guanidinoacetate N-methyltransferase -- GAPDH glyceraldehyde-3-phosphate dehydrogenase -- GDH glutamate dehydrogenase -- GLS2 glutaminase 2 -- GLUT1 glucose transporter 1 -- GMPS guanine monophoshate synthetase -- GNMT glycine N-Methyltransferase -- GPI glucose-6-phosphate isomerase -- GPT2 glutamic-pyruvic transaminase 2 -- HIF1 hypoxia-inducible factor 1 -- HK2 hexokinase 2 -- HMGCR 3-hydroxy-3-methylglutaryl-CoA reductase -- IDH3α isocitrate dehydrogenase 3α -- IFN- γ Interferon γ -- IL2 interleukin 2 -- IMP inosine monophosphate -- LDHA lactate dehydrogenase A -- MCD malonyl-CoA decarboxylase -- MCT1/2 monocarboxylate transporter 1/2 -- MDM2 mouse double minute 2 homolog -- MDSCs myeloid-derived suppresser cells -- ME1/2 malic enzyme 1/2 -- MTHFD2 methylenetetrahydrofolate dehydrogenase 2 -- mTORC1 mammalian target of rapamycin complex 1 -- ND1 NADH dehydrogenase subunit 1 -- NRF2 nuclear factor erythroid 2-related factor 2 -- NSCLC non-small cell lung cancer -- p300 E1A binding protein p300 -- p53R2/RRM2B ribonucleotide reductase regulatory TP53inducible subunit M2B -- P5CS pyrroline-5-carboxylate synthase -- PANK1 pantothenate kinase 1 -- PARK2 Parkin RBR E3 Ubiquitin Protein Ligase -- PDC pyruvate dehydrogenase complex -- PDK pyruvate dehydrogenase kinase 1 -- PFAS phosphoribosylformylglycinamidine synthase -- PFK phosphofructokinase -- PFKFB 6-phosphofructo-2-kinase/fructose-2, 6-biphosphatase -- PFKM phosphofructokinase, muscle -- PGK phosphoglycerate kinase -- PGM1 phosphoglucomutase 1 -- PHGDH phosphoglycerate dehydrogenase -- PI3K phosphatidylinositol-3-kinase -- PKM1/2 Pyruvate kinase M1/2 -- PON2 paraoxonase 2 -- PPA inorganic pyrophosphatase -- PPARs peroxisome proliferator-activated receptors -- PPAT phosphoribosyl pyrophosphate amidotransferase -- PPP pentose phosphate pathway -- PRKAA2 protein kinase AMP-activated catalytic subunitalpha 2 -- PRODH/POX proline dehydrogenase/proline oxidase -- PROTAC Proteolysis-targeting chimera -- PRPS2 phosphoribosyl pyrophosphate synthetase 2 -- PSAT1 phosphoserine aminotransferase 1 -- PSPH phosphoserine phosphatase -- PTEN phosphatase and tensin homolog -- PYCR pyrroline-5-carboxylate reductase 1 -- SAM S-adenosyl-methionine -- SCD stearoyl-CoA desaturase -- SCO2 synthesis of cytochrome c oxidase 2 -- SHMT1/2 serine hydroxymethyltransferases 1/2 -- SLC43A1 solute carrier family 43 member 1 -- SLC7A5 solute carrier family 7 member 5 -- SNAT5/SCL38A5 sodium-coupled neutral amino acid transporter5/solute carrier family 38 member 5 -- SREBP-1 sterol regulatory element-binding protein 1 -- STAT3 signal transducer and activator of transcription3 -- TALDO1 transaldolase 1 -- TIGAR TP53 induced glycolysis regulatory phosphatase -- TKT transketolase -- TP53 mutant tumor protein 53 -- TSC1/2 tuberous sclerosis complex subunit 1 -- UMP uridine monophosphate -- VEGF vascular endothelial growth factor -- VHL von Hippel–Lindau tumor suppressor; Cell metabolism -- Transcription factors -- Metabolic reprogramming -- Signaling metabolites -- Cancer treatment; Cancer -- Periodicals; Neoplasms -- Periodicals; Review Literature; Cancer -- Périodiques; Electronic journals; 616.994
• DOI: 10.1016/j.semcancer.2022.10.001
• Languages: English
• ISSNs: 1044-579X

Abstract

Abstract: Metabolic reprogramming is an important cancer hallmark that plays a key role in cancer malignancies and therapy resistance. Cancer cells reprogram the metabolic pathways to generate not only energy and building blocks but also produce numerous key signaling metabolites to impact signaling and epigenetic/transcriptional regulation for cancer cell proliferation and survival. A deeper understanding of the mechanisms by which metabolic reprogramming is regulated in cancer may provide potential new strategies for cancer targeting. Recent studies suggest that deregulated transcription factors have been observed in various human cancers and significantly impact metabolism and signaling in cancer. In this review, we highlight the key transcription factors that are involved in metabolic control, dissect the crosstalk between signaling and transcription factors in metabolic reprogramming, and offer therapeutic strategies targeting deregulated transcription factors for cancer treatment.